Swiss hepatitis C sufferers to get full access to expensive drug

The Federal Office of Public Health has announced that it will make the hepatitis C drug Zepatier available to all patients from July 1. The 12-week treatment costs CHF31,000 ($31,952) per patient and was previously only available to those with an advanced form of the disease. Zepatier is produced by pharma company Merck Sharp & Dohme and is a unique combination of drugs elbasvir and grazoprevir. It is effective for patients infected with genotype 1 a

France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment

The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines. According to the ministry’s press release (in French), the price decrease for the drugs Harvoni and Sovaldi is described as “very substantial.” New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for